DOCSLIB.ORG

FOI 073-1718 Document 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FOI 073-1718 Document 3 Document 3 PEP005 (ingenol mebutate) Gel 0000 2.7.4 Summary of Clinical Safety CONFIDENTIAL PEP005 (ingenol mebutate) Gel 2.7.4 Summary of Clinical Safety for Actinic Keratosis LEO Pharma A/S Clinical Development 29 May 2011 THIS DOCUMENT CONTAINS TRADE SECRETS, OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELIVERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S - LEO PHARMACEUTICAL PRODUCTS LTD. A/S 00255345v 2.0 PEP005 (ingenol mebutate) Gel 0000 2.7.4 Summary of Clinical Safety PEP005 (ingenol mebutate) Gel Page 2 of 168 2.7.4 Summary of Clinical Safety for Actinic Keratosis 29 May 2011 Module 2 Summary of Clinical Safety TABLE OF CONTENTS TABLE OF CONTENTS ......................................................................................................... 2 TABLE OF TABLES ............................................................................................................... 5 TABLE OF FIGURES ............................................................................................................. 8 TABLE OF ATTACHMENTS ............................................................................................... 9 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..................................... 10 1 EXPOSURE TO THE DRUG ............................................................................................ 12 1.1 OVERALL SAFETY EVAULATION PLAN AND NARRATIVES OF SAFETY STUDIES .......................................................................................................................... 13 1.1.1 Studies in the PEP005 Gel Development Program ......................................................... 13 1.1.2 Development Plan for PEP005 Gel in Actinic Keratosis ................................................ 15 1.1.3 Summary of All Investigations Pertinent to Safety ......................................................... 16 1.1.3.1 Tabular Summaries of Clinical Studies ........................................................................ 16 1.1.4 Methods and Definitions ................................................................................................. 28 1.1.5 Analysis Populations ....................................................................................................... 28 1.1.5.1 Adverse Events ............................................................................................................. 30 1.1.5.2 Serious Adverse Events ................................................................................................ 30 1.1.5.3 Local Skin Responses ................................................................................................... 31 1.1.5.4 Pigmentation and Scarring ........................................................................................... 32 1.2 OVERALL EXTENT OF EXPOSURE ............................................................................. 33 1.2.1 Disposition ...................................................................................................................... 33 1.2.2 Extent of Exposure .......................................................................................................... 35 1.3 DEMOGRAPHIC AND OTHER CHARACTERISTICS OF STUDY POPULATION ... 39 2 ADVERSE EVENTS ........................................................................................................... 44 2.1 ANALYSIS OF ADVERSE EVENTS .............................................................................. 44 2.1.1 Common Adverse Events ................................................................................................ 46 2.1.1.1 Treatment-related Adverse Events ............................................................................... 49 2.1.1.2 Adverse Events by Severity ......................................................................................... 51 2.1.1.3 Treatment-related Severe Adverse Events ................................................................... 53 2.1.1.4 Analysis of Adverse Events across PEP005 Gel Concentration .................................. 54 2.1.1.5 Effects of Dosing Regimen and Treatment Location ................................................... 57 2.1.1.6 Effect of Multiple Treatments of PEP005 Gel ............................................................. 57 THIS DOCUMENT CONTAINS TRADE SECRETS, OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELIVERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S - LEO PHARMACEUTICAL PRODUCTS LTD. A/S 00255345v 2.0 PEP005 (ingenol mebutate) Gel 0000 2.7.4 Summary of Clinical Safety PEP005 (ingenol mebutate) Gel Page 3 of 168 2.7.4 Summary of Clinical Safety for Actinic Keratosis 29 May 2011 2.1.1.7 Combined Adverse Events and Local Skin Responses ................................................ 58 2.1.2 Deaths .............................................................................................................................. 61 2.1.3 Other Serious Adverse Events ......................................................................................... 61 2.1.3.1 Serious Adverse Events Reported in Studies Evaluating Field Application of Study Medication for Treatment of AK Lesions ............................................................... 62 2.1.3.1.1 Squamous Cell Carcinoma Reported during Studies Evaluating Field Application of Study Medication for Treatment of AK Lesions ...................................... 66 2.1.3.2 Serious Adverse Events in Lesion-specific and Non-AK Studies ............................... 67 2.1.3.3 Serious Adverse Events from Ongoing Studies ........................................................... 69 2.1.4 Other Significant Adverse Events ................................................................................... 69 2.1.4.1 Adverse Events Leading to Discontinuation ................................................................ 69 2.1.4.1.1 Adverse Events Leading to Discontinuation from the Study .................................... 70 2.1.4.1.2 Adverse Events Leading to Discontinuation of Treatment ....................................... 73 2.1.5 Analysis of Adverse Events by Organ System or Syndrome .......................................... 76 2.1.5.1 Infections and Infestations ........................................................................................... 76 2.1.5.2 Neoplasms .................................................................................................................... 79 2.1.5.3 Eye Disorders ............................................................................................................... 80 2.1.5.4 Cardiac Disorders ......................................................................................................... 81 2.1.6 Long-term Adverse Effects ............................................................................................. 82 2.1.6.1 Study Patients ............................................................................................................... 82 2.1.6.2 Safety through 12 Months of Follow-up ...................................................................... 84 2.2 NARRATIVES ................................................................................................................... 85 3 CLINICAL LABORATORY EVALUATIONS ............................................................... 86 4 VITAL SIGNS, PHYSICAL FINDINGS, AND OTHER OBSERVATIONS RELATED TO SAFETY ................................................................................................ 87 4.1 VITAL SIGNS ................................................................................................................... 87 4.2 ELECTROCARDIOGRAM RESULTS ............................................................................ 88 4.2.1 ECG Intervals .................................................................................................................. 88 4.2.2 ECG Abnormalities Reported as Adverse Events ........................................................... 91 4.2.3 Cardiac Safety Testing .................................................................................................... 94 4.3 LOCAL SKIN RESPONSE ............................................................................................... 94 4.3.1 Composite LSR Scores .................................................................................................... 94 4.3.1.1 Evaluation of Treatment Regimen and Mean Maximum LSR Composite Score ........ 97 4.3.1.2 Evaluation of Multiple Treatments of PEP005 Gel on Maximum LSR Composite Scores ................................................................................................................................ 97 THIS DOCUMENT CONTAINS TRADE SECRETS, OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELIVERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S - LEO PHARMACEUTICAL PRODUCTS LTD. A/S 00255345v 2.0 PEP005 (ingenol mebutate) Gel 0000 2.7.4 Summary of Clinical Safety PEP005 (ingenol mebutate) Gel Page 4 of 168 2.7.4 Summary of Clinical Safety for Actinic Keratosis 29 May 2011 4.3.2 Individual Local Skin Responses ...................................................................................
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • S41598-020-80397-9.Pdf
    www.nature.com/scientificreports OPEN Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes Jason K. Cullen1, Glen M. Boyle1,2,3,7*, Pei‑Yi Yap1, Stefan Elmlinger1, Jacinta L. Simmons1, Natasa Broit1, Jenny Johns1, Blake Ferguson1, Lidia A. Maslovskaya1,4, Andrei I. Savchenko4, Paul Malek Mirzayans4, Achim Porzelle4, Paul V. Bernhardt4, Victoria A. Gordon5, Paul W. Reddell5, Alberto Pagani6, Giovanni Appendino6, Peter G. Parsons1,3 & Craig M. Williams4* The long‑standing perception of Protein Kinase C (PKC) as a family of oncoproteins has increasingly been challenged by evidence that some PKC isoforms may act as tumor suppressors. To explore the hypothesis that activation, rather than inhibition, of these isoforms is critical for anticancer activity, we isolated and characterized a family of 16 novel phorboids closely‑related to tigilanol tiglate (EBC‑46), a PKC‑activating epoxytigliane showing promising clinical safety and efcacy for intratumoral treatment of cancers. While alkyl branching features of the C12‑ester infuenced potency, the 6,7‑epoxide structural motif and position was critical to PKC activation in vitro. A subset of the 6,7‑epoxytiglianes were efcacious against established tumors in mice; which generally correlated with in vitro activation of PKC. Importantly, epoxytiglianes without evidence of PKC activation showed limited antitumor efcacy. Taken together, these fndings provide a strong rationale to reassess the role of PKC isoforms in cancer, and suggest in some situations their activation can be a promising strategy for anticancer drug discovery. Te Protein Kinase C (PKC) family of serine/threonine kinases was frst identifed almost 40 years ago1.
    [Show full text]
  • The Effect of Wool Hydrolysates on Squamous Cell Carcinoma Cells in Vitro
    RESEARCH ARTICLE The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment Tatsiana Damps1*, Anna Katarzyna Laskowska1, Tomasz Kowalkowski2,3, Monika Prokopowicz4, Anna Katarzyna Puszko5, Piotr Sosnowski1, Joanna Czuwara6, Marek Konop6, Krzysztof RoÂżycki4, Joanna Karolina Borkowska7, Aleksandra Misicka1, Lidia Rudnicka1 1 Department of Neuropeptides, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland, 2 Chair of Environmental Chemistry and Bioanalytics, Faculty of Chemistry, Nicolaus a1111111111 Copernicus University, Toruń, Poland, 3 Interdisciplinary Centre of Modern Technology, Nicolaus Copernicus a1111111111 University, Toruń, Poland, 4 Laboratory of Chemical Synthesis, CePT, Mossakowski Medical Research a1111111111 Centre, Polish Academy of Sciences, Warsaw, Poland, 5 Faculty of Chemistry, University of Warsaw, a1111111111 Warsaw, Poland, 6 Department of Dermatology, Medical University of Warsaw, Warsaw, Poland, 7 Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, a1111111111 Warsaw, Poland * [email protected] OPEN ACCESS Abstract Citation: Damps T, Laskowska AK, Kowalkowski T, Prokopowicz M, Puszko AK, Sosnowski P, et al. Squamous cell carcinoma of the skin is the second most common cutaneous malignancy. (2017) The effect of wool hydrolysates on Despite various available treatment methods and advances in noninvasive diagnostic tech- squamous cell carcinoma cells in vitro. Possible niques, the incidence of metastatic cutaneous squamous cell carcinoma is rising. Deficiency implications for cancer treatment. PLoS ONE 12 (8): e0184034. https://doi.org/10.1371/journal. in effective preventive or treatment methods of transformed keratinocytes leads to necessity pone.0184034 of searching for new anticancer agents. The present study aims to evaluate the possibility of Editor: Andrzej T Slominski, University of Alabama using wool hydrolysates as such agents.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Standard Prior Authorization Medication List July, 2017
    Standard Prior Authorization Medication List July, 2017 Drug Class or Disease Medication Name(s) Acne - oral Absorica® (isotretinoin) Acne - oral antibiotics Doryx®, Adoxa®, Monodox®, Solodyn®, Acticlate®, Oracea® Acanya® (clindamycin/benzoyl peroxide) 1.2%-2.5% gel, Atralin® (tretinoin) 0.05% gel, cream, Onexton® Acne - topical (clindamycin/benzoyl peroxide), Avar LS® (sulfacetamide/sulfur), Clindagel® (clindamycin) gel 1%, Ziana® (clindamycin/tretinoin), Retin-A MicroGel® (tretinoin) Carac® (fluorouracil) cream 5%, Zyclara® (imiquimod) 2.5% & Actinic keratosis 3.75% cream, Picato® (ingenol mebutate) gel Allergic Reaction Auvi-Q®, EPIPEN-JR® (epinephrine ) Anabolic androgens Testosterone Analgesia – topical Lido-K® (lidocaine) 3% lotion Antibiotic - topical Nuvessa® Gel 1.3% Anticonvulsant Trokendi ®XR Antidiabetic medications Glumetza® (metformin ER), Ertaczo® 2% cream (sertaconazole), Xolegel® 2% Gel Antifungal - topical (ketoconazole) Antifungal – oral Oravig® (miconazole) buccal tab Antihypertensive Epaned® (enalapril) soln Zovirax® 5% cream (acyclovir), Denavir® 1% cream Antiviral - topical (penciclovir); Xerese® (acyclovir-hydrocortisone) cream 5-1% Vimovo® (naproxen-esomeprazole), Duexis® (ibuprofen- Combination medications famotidine), Treximet® (sumatriptan-naproxen) Clobex® (clobetasol) spray 0.05%, Trianex® (triamcinolone) Corticosteroids - topical oint., Verdeso® (desonide) 0.05% foam, Locoid® (hydrocortisone) 0.1% cream, lotion, oint. Enterocolitis Donnatal® (phenobarbital/atropine/scopolamine) External warts (condylomata
    [Show full text]
  • Changes to the Highmark Drug Formularies
    November 2015 CHANGES TO THE HIGHMARK DRUG FORMULARIES FOURTH QUARTER UPDATE The Fourth Quarter 2015 update to our Drug Formularies and pharmaceutical management procedures is attached to this Special Bulletin. The formularies and pharmaceutical management procedures are updated on a quarterly basis, and the attached changes reflect the decisions made in September 2015 by the Highmark Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout the document. Please reference the guide below to navigate this communication: Highmark Comprehensive and Progressive Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Health Care Reform Formulary B. Updates to the Pharmacy Utilization Management Programs 1. Updates to the Prior Authorization Program 2. Updates to the Managed Prescription Drug Coverage (MRxC) Program 3. Updates to the Quantity Level Limit (QLL) Program As an added convenience, you can also search our drug formularies on the Provider Resource Center (accessible via NaviNet® or our website, highmarkbcbsde.com). Click the Pharmacy/Formulary Information link from the menu on the left. If you have any questions regarding this pharmacy communication or the formularies, please contact your Highmark Blue Cross Blue Shield Delaware Provider Relations Representative. (Continued on next page) Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. Blue Cross, Blue Shield and the Cross and Shield symbols are registered service marks of the Blue Cross and Blue Shield Association. Highmark is a registered mark of Highmark Inc. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides a secure, web-based portal between providers and health insurance companies.
    [Show full text]
  • Pharmacy Auditing and Dispensing Job Aid: Billing Kits
    Pharmacy Auditing and Dispensing Job Aid: Billing Kits PharmacistsJOB and their staff members have a responsibility toAID ensure patients receive the correct medication in the correct dosage form. The correct billing of selected dosage forms can sometimes be difficult to decipher. A National Council for Prescription Drug Programs (NCPDP) pharmacist explains, “Billing unit errors can have serious consequences when State Medicaid agencies are involved, as underpayment or overpayment of rebates could generate a fraud investigation by the State or by the Centers for Medicare and Medicaid Services (CMS).”[1] The NCPDP billing unit standard (BUS) helps pharmacists and staff members submit accurate claims for pharmaceutical products. NCPDP created the BUS to provide guidance to pharmacy claims software developers and to promote uniformity and consistency across standard billing units.[2] The standards implemented by NCPDP address billing unit inconsistencies in the health care delivery industry that may result in incorrect reimbursement or difficulties defining what constitutes a billing unit. The standards provide a consistent and well-defined billing unit for use in pharmacy transactions, provide a method to assign a standard billing unit, reduce the time it takes for a pharmacist to accurately bill a prescription and get paid correctly, provide a standard billing unit for use in the calculation of accurate reimbursement, and provides a standard size unit of measure for use in drug utilization review.[3] The BUS employs only three billing units to describe any and all drug products. These billing units are milliliter, gram, and each.[4] Items billed as “milliliter” include any product measured by liquid volume, such as injectable products of 1 milliliter or greater, reconstitutable non-injectable products at the final volume after reconstitution, and some inhalers.
    [Show full text]
  • Division of Developmental Disabilities Fee-For-Service Program Drug List (DL) INTRODUCTION
    Janice K. Brewer Clarence H. Carter Governor Director Division of Developmental Disabilities Fee-For-Service Program Drug List (DL) INTRODUCTION The Division of Developmental Disabilities (DDD) is pleased to provide the DDD Fee-For-Service (FFS) Program Drug List (DL) to be used when prescribing medications for DDD FFS members. For clarification, this DL is only for the DDD FFS members. This DL does not apply to DDD members enrolled in any of the DDD Managed Care Contractors’ Health Plans. This document provides general information regarding the DDD pharmacy benefit for FFS members. The drugs listed in the DL are intended to provide clinically appropriate, cost-effective options for DDD FFS members who require medically necessary treatment. The drugs listed on the DL have been reviewed and approved by the Arizona Health Care Cost Containment System (AHCCCS) Pharmacy and Therapeutics (P&T) Committee. However, the DL is not intended as a comprehensive listing of all drugs that may be reimbursed by DDD. If a drug is not listed on the DL and is determined to be medically necessary, it may be requested through the prior authorization process. MedImpact is the Pharmacy Benefit Manager (PBM) for the DDD FFS Program. MedImpact will facilitate the administration of the pharmacy benefit for the following populations: Members who are Dual Eligibles (DDD FFS members who are also eligible for Medicare) Members enrolled in DDD’s American Indian Health Program (AIHP) Members may obtain additional pharmacy information on the MedImpact website at www.medimpact.com/members Members and prescribing clinicians may also contact the MedImpact Customer Service Center at 1 (800) 788-2949, 24 hours per day, 365 days per year.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 29, No. 3, 2015 WHO Drug Information Contents Norms and standards 342 Antibiotics FDA regulation on use of antibiotics in food- 305 Assessing new medical products in health producing animals emergencies: the EUAL procedures 343 Herbal medicines EMA publishes scientific opinions on herbal medicines Medicines for women and children 343 Collaboration 324 Quality and availability of selected life-saving CFDA joins the ICMRA Interim Management reproductive health medicines in developing Committee ; PMDA publishes 2015 Strategic countries International Plan; EU and Swiss regulators sign confidentiality arrangement; First international generic drug regulators’ meeting Safety news held; Central African countries aim for 334 Restrictions regulatory harmonization Repaglinide : contraindicated with clopidogrel; 344 Law enforcement 334 Safety warnings Operation Pangea VIII nets record amount of Sitagliptin, saxagliptin, linagliptin, alogliptin : potentially dangerous products severe joint pain; Anagliptin : intestinal obstruction ; SGLT2 inhibitors : atypical diabetic ketoacidosis; Epoetin 345 Successful Phase III trial beta : possible increased risk of retinopathy in preterm infants; Adefovir pivoxil : fractures; Ingenol mebutate : Ebola vaccine : shown to be highly effective severe allergic reactions and herpes zoster; Asunaprevir, daclatasvir : decreased hepatic residual function; Influenza HA 345 Approved vaccine : optic neuritis; Abiraterone acetate : fulminant hepatitis, hepatic failure; Fingolimod : Rolapitant : for
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION November 2020 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems. The aim of harmonisation is to reach a “full” agreement of all mono substances in a given class as listed in the WHO ATC Index, mainly at third level: whenever this is not possible, or harmonisation of third level is too difficult or makes no sense (e.g.
    [Show full text]
  • Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs
    2020 Formulary List of covered prescription drugs This drug list applies to all Large Group HMO and Large Group POS products, and the following Small Group HMO products: HMO GF 1, HMO GF 2, HMO GF 3, HMO GF 4, HMO GF 5, HMO GF 6, HMO GF 7, Bronze HDHP NG 1, CalChoice Bronze HDHP NG 3, CalChoice Bronze HMO NG 2, CalChoice Silver HMO NG 1, CalChoice Silver HMO NG 2, CalChoice Silver HMO NG 3, Silver HMO NG 1, Silver HMO NG 2, CalChoice Gold HMO NG 2, CalChoice Gold HMO NG 3, CalChoice Gold HMO NG 5, Gold HMO NG 1, Gold HMO NG 2, Gold HMO NG 3, Gold HMO NG 4, Gold HMO NG 5, Gold HMO NG 6, Gold HMO NG 7, CalChoice Platinum HMO NG 1, CalChoice Platinum HMO NG 2, CalChoice Platinum HMO NG 3, Platinum HMO NG 1, Platinum HMO NG 2, Platinum HMO NG 3, Platinum HMO NG 4, Platinum HMO NG 7, Platinum HMO NG 8 List of covered prescription drugs for Employer-sponsored plans from Sharp Health Plan An electronic version of this Prescription Drug List is available on the Sharp Health Plan website, by visiting sharphealthplan.com/search-drug-list You can find specific cost sharing information in your plan’s coverage documents by logging in to your Sharp Connect account on our website by visiting sharphealthplan.com/login This document is subject to change and all previous versions are no longer in effect. Last updated 12/01/2020. Table of Contents Introduction i-xii Definitions i How often does the Formulary change? iii Will I be notified of a Formulary change? iii How do I locate a Prescription Drug on the Formulary? iv How do I know if the drug listed
    [Show full text]